MDTFEA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MDTFEA, also known as 3,4-methylenedioxy-N-(2,2,2-trifluoroethyl)amphetamine, is a chemical compound and possible psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to the entactogen MDEA.[1][2][3] It is the derivative of MDEA in which the ethyl group on the amine has been replaced with a trifluoroethyl group.[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | MDTFE; MDCF3; 3,4-Methylenedioxy-N-(2,2,2-trifluoroethyl)amphetamine; N-(2,2,2-Trifluoroethyl)-3,4-methylenedioxyamphetamine |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C12H14F3NO2 |
| Molar mass | 261.244 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alexander Shulgin briefly described MDTFEA in his book PiHKAL (Phenethylamines I Have Known and Loved).[1][3] Based on personal communication to Shulgin, it was described as "possibly active".[1] The drug was tested at a highest total dose of 500 mg orally, which was given in three divided doses over a period of 5 or 6 hours.[1][2][3] The effects included only a very mild intoxication and little or no sympathomimetic effects, with these possible effects being short-lasting.[1] For comparison, MDEA has a listed dose of 100 to 200 mg orally and a duration of 3 to 5 hours.[1][2][3] Daniel Trachsel has said that MDTFEA seems to be inactive.[2][3]
The chemical synthesis of MDTFEA has been described.[1]
MDTFEA was first described in the scientific literature by Shulgin in PiHKAL in 1991.[1] It was not synthesized or tested by Shulgin but was instead described to him via personal communication.[1]